Results 81 to 90 of about 13,977 (118)
JQ1 reduces oxidative stress-enhanced IL-6 and CXCL8 expression in NHBE cells.
, 2014 NHBE cells pre-treated with JQ1 but not JQ1(-) (both at 5×10−9−10−6 M) reduced IL-1β induced release of IL-6 (A) and CXCL8 (B) in a concentration-dependent manner.
Younis M. Khan (554747) +3 more
core +1 more source
BET Inhibitor JQ1 Attenuates Atrial Fibrillation Through Modulation of Fibrosis, Calcium Homeostasis, and Mitochondrial Function in a Murine Model [PDF]
Bromodomain and extraterminal domain (BET) proteins act as epigenetic regulators of gene transcription. BET inhibitors have shown therapeutic potential in various models of heart failure; however, their efficacy in atrial fibrillation (AF) remains ...
Murakoshi, Nobuyuki +7 more
core +1 more source
, 2022 Die niedermolekulare Verbindung (engl. small molecule) JQ1 hemmt kompetitiv die Bromodomänen der zur bromodomain and extra-terminal domain (BET) Familie gehörenden Proteine BRD2, BRD3 und BRD4, welche als epigenetische Lesedomänen auf die Transkription ...
Schlichting, Jara Pascale
core
Effects of JQ1 on P-TEFb occupancy.
, 2014 BAL17 and Raji cells were either untreated or treated with 1 µM of JQ1 for 2 hours. Recruitment of P-TEFb was detected by ChIP assays. Each experiment was analyzed in triplicate via real-time PCR, performed twice, and is reported as the mean and standard
David H. Price (31011) +8 more
core +1 more source
[South African Rys., Engine Drawing Card, Sketch No. 6651]
, 1918 This engine drawing card was created for South African Railways, Class 14-38 1/4 F. Section H-14 1/4 F. Sketch 6651.
Baldwin Locomotive Works
core
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma. [PDF]
Elife, 2020 Pal A +10 more
europepmc +1 more source
BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells
, 2017 Anaplastic thyroid carcinoma (ATC) represents the most lethal thyroid cancer sub-type, currently unresponsive to standard treatments. Recently, bromodomain and extra-terminal (BET) proteins have emerged as attractive therapeutic targets in several ...
Catia Mio +17 more
core +1 more source
, 2019 Aim JQ1, a BET bromodomain inhibitor, is a promising therapeutic approach for bladder cancer (BC). Our study aimed to determine whether autophagy is induced by JQ1 and its potential role toward proliferation in BC.
Hai‐Bao Zhang +10 more
core +1 more source
The bromodomain inhibitor (+)-JQ1 is a highly validated chemical probe; however, it exhibits poor in vivo pharmacokinetics. To guide efforts toward improving its pharmacological properties, we identified the (+)-JQ1 primary metabolite using chemical ...
Feng Li (30515) +15 more
core +1 more source
Inhibidores BET. El singular compuesto (+)-JQ1 [PDF]
, 2015 The serendipitous discovery of (bromodomain extra-terminal) (BET) inhibitors, especially of the BRD4 bromodomain inhibitors, has allowed modulation of gene transcription with epigenetic drugs.
Avendaño, Carmen
core +7 more sources